BONRAYBIO (6955) Annual Reports
Listed on the Taiwan Stock Exchange (TWSE), classified under Healthcare. This page collects the company's annual reports, with files served directly by the Market Observation Post System (MOPS).
Company profile
- Sector： All Healthcare stocks →
- Listing date： 2024-12-06
- Incorporated： 2016-01-12
- Paid-in capital： NT$248m
Website：Official site ↗
Financial history
Taiwan filings are cumulative; figures here are restated to single quarters.
Show table：Income statement
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 48.2 | 54.6 | 57.0 | 63.0 | 71.0 | 79.8 | 73.3 | 82.2 | 84.4 | 92.3 |
| Gross profit | — | — | — | — | 37.7 | 43.7 | 44.5 | 49.0 | 55.4 | 63.0 | 56.9 | 63.3 | 64.5 | 72.4 |
| Operating income | — | — | — | — | 11.5 | 14.7 | 14.4 | 20.3 | 22.7 | 27.9 | 22.9 | 26.4 | 25.5 | 30.5 |
| Pre-tax income | — | — | — | — | 14.3 | 16.5 | 14.0 | 23.6 | 24.8 | 23.4 | 26.2 | 30.3 | 28.0 | 32.8 |
| Net income | — | — | — | — | 14.3 | 16.5 | 14.0 | 23.6 | 24.1 | 22.8 | 25.8 | 29.8 | 23.9 | 28.4 |
Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.
Show table：Balance sheet
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | 225 | 241 | 241 | 272 | 287 | 300 | 317 | 578 | 580 | 571 | 597 | 651 | 649 | 640 |
| Total assets | 263 | 280 | 290 | 317 | 331 | 346 | 362 | 623 | 640 | 634 | 662 | 720 | 727 | 723 |
| Current liabilities | 19.5 | 24.1 | 19.8 | 28.6 | 32.4 | 31.9 | 34.5 | 44.5 | 70.3 | 43.7 | 45.9 | 74.7 | 95.4 | 64.1 |
| Total liabilities | 25.6 | 27.2 | 31.5 | 38.8 | 41.8 | 40.5 | 42.3 | 51.5 | 76.4 | 49.0 | 50.3 | 78.5 | 98.4 | 66.2 |
| Equity | 237 | 253 | 259 | 278 | 289 | 306 | 320 | 571 | 563 | 585 | 611 | 641 | 628 | 657 |
Positive = cash in, negative = cash out.
Show table：Cash flow statement
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | — | — | 16.3 | 12.4 | 21.5 | 30.0 | 4.64 | 33.6 | 23.8 | 38.0 | 18.5 | 16.5 |
| Investing | — | — | — | — | -1.79 | -5.11 | -2.13 | -2.42 | -163 | -76.1 | -43.0 | 63.2 | -11.7 | -45.3 |
| Financing | — | — | — | — | -0.76 | -4.18 | -0.77 | 227 | -0.81 | -33.2 | -0.82 | 14.2 | -15.8 | -38.0 |
| Cash at period end | 70.0 | 89.4 | 90.8 | 117 | 133 | 136 | 153 | 410 | 255 | 174 | 155 | 271 | 264 | 197 |
Gross, operating and net margin = the respective profit ÷ revenue.
Show table：Profitability
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 78.3% | 80.0% | 78.0% | 77.8% | 77.9% | 79.0% | 77.6% | 77.0% | 76.4% | 78.5% |
| Operating margin | — | — | — | — | 23.9% | 26.8% | 25.3% | 32.3% | 32.0% | 34.9% | 31.3% | 32.1% | 30.2% | 33.0% |
| Net margin | — | — | — | — | 29.6% | 30.1% | 24.6% | 37.4% | 33.9% | 28.5% | 35.3% | 36.3% | 28.4% | 30.8% |
ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.
Show table：Returns & leverage
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | 16.1% | 18.3% | 19.0% | 20.7% | 16.9% | 17.2% | 17.4% |
| ROA | — | — | — | — | — | — | — | 14.5% | 16.1% | 17.2% | 18.8% | 15.3% | 15.0% | 15.9% |
| Debt ratio | 9.8% | 9.7% | 10.9% | 12.2% | 12.6% | 11.7% | 11.7% | 8.3% | 11.9% | 7.7% | 7.6% | 10.9% | 13.6% | 9.2% |
Show table：EPS
| Item | 2021Q4 | 2022Q4 | 2023Q2 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS（NT$） | — | — | — | — | 0.83 | 0.73 | 0.72 | 1.17 | 1.12 | 1.05 | 0.76 | 1.20 | 0.97 | 1.14 |
Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.
Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.
Positive = cash in, negative = cash out.
Gross, operating and net margin = the respective profit ÷ revenue.
ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.
Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.
Show table：Income statement
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 223 | 306 |
| Gross profit | 175 | 239 |
| Operating income | 61.0 | 100.0 |
| Pre-tax income | 68.4 | 105 |
| Net income | 68.4 | 103 |
Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.
Show table：Balance sheet
| Item | 2024 | 2025 |
|---|---|---|
| Current assets | 578 | 651 |
| Total assets | 623 | 720 |
| Current liabilities | 44.5 | 74.7 |
| Total liabilities | 51.5 | 78.5 |
| Equity | 571 | 641 |
Positive = cash in, negative = cash out.
Show table：Cash flow statement
| Item | 2024 | 2025 |
|---|---|---|
| Operating | 80.1 | 100.0 |
| Investing | -11.4 | -219 |
| Financing | 221 | -20.6 |
| Cash at period end | 410 | 271 |
Gross, operating and net margin = the respective profit ÷ revenue.
Show table：Profitability
| Item | 2024 | 2025 |
|---|---|---|
| Gross margin | 78.5% | 77.9% |
| Operating margin | 27.4% | 32.6% |
| Net margin | 30.7% | 33.5% |
ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.
Show table：Returns & leverage
| Item | 2024 | 2025 |
|---|---|---|
| ROE | 12.0% | 16.9% |
| ROA | 11.0% | 15.3% |
| Debt ratio | 8.3% | 10.9% |
Show table：EPS
| Item | 2024 | 2025 |
|---|---|---|
| EPS（NT$） | 3.45 | 4.13 |
Source: Taiwan MOPS financial statements
BONRAYBIO annual reports
About BONRAYBIO filings
Where can I download BONRAYBIO (6955) annual reports?
Every financial year in the table above links straight to the PDF filed with the Market Observation Post System (MOPS), Taiwan's statutory disclosure platform. 2 years are available in English, within a range covering 2024 to 2025.
Why are some years Chinese only?
Filing an English annual report is only mandatory for larger Taiwanese issuers; smaller companies and those on the Emerging Stock Board file in Chinese. Where no English edition exists this site links the Chinese PDF rather than leaving the year blank, so you can still reach the document.
What is an investor conference (法人說明會)?
It is the Taiwanese equivalent of an earnings call or analyst briefing. Listed companies present quarterly results and outlook, and file the presentation deck with MOPS — usually in both Chinese and English. Many also publish a webcast recording.
How does Taiwan's reporting calendar work?
Taiwanese issuers file quarterly financial reports plus an annual report, and publish monthly revenue figures — a disclosure cadence that is more frequent than Hong Kong or Singapore. Financial years are numbered using the ROC calendar (ROC 114 = 2025); this site shows both.
Browse all Taiwan listed companies, or read this page in Chinese — the Chinese edition also carries the letter to shareholders and the revenue breakdown.